-

Evolus to Participate in the Virtual 11th Annual SVB Leerink Global Healthcare Conference

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced that members of its management team will be participating in the Virtual 11th Annual SVB Leerink Global Healthcare Conference.

Event:

Virtual 11th Annual SVB Leerink Global Healthcare Conference

Date:

Wednesday, February 16, 2022

Time:

4:20pm – 4:50pm ET

An audio webcast of this event will be available on the investor relations section of Evolus’ website at www.evolus.com. A replay of the webcast will be available for 90 days after the date of the presentation.

About Evolus, Inc.

Evolus (Nasdaq: EOLS) is a performance beauty company with a customer-centric approach to delivering breakthrough products. Approved in 2019 by the U.S. Food and Drug Administration, Jeuveau® (prabotulinumtoxinA-xvfs) is the first and only neurotoxin dedicated exclusively to aesthetics and manufactured in a state-of-the-art facility using Hi-Pure™ technology. Jeuveau® is powered by Evolus’ unique technology platform and is designed to transform the aesthetic market by eliminating the friction points existing for customers today. Visit us at www.evolus.com and follow us on LinkedIn, Twitter, Instagram or Facebook.

Jeuveau® is a registered trademark of Evolus, Inc.

Hi-Pure™ is a trademark of Daewoong Pharmaceutical Co, Ltd.

Contacts

Investor/Media Contact:
David K. Erickson, Evolus, Inc.
Vice President, Investor Relations
Tel: 949-966-1798
Email: david.erickson@evolus.com

Industry:

Evolus, Inc.

NASDAQ:EOLS
Details
Headquarters: Newport Beach, CA
CEO: David Moatazedi
Employees: 150
Organization: PUB
Release Summary
Evolus announces that members of its management team will be participating in the Virtual 11th Annual SVB Leerink Global Healthcare Conference.
Release Versions
English
$Cashtags
$EOLS

Contacts

Investor/Media Contact:
David K. Erickson, Evolus, Inc.
Vice President, Investor Relations
Tel: 949-966-1798
Email: david.erickson@evolus.com

Social Media Profiles
Follow us on LinkedIn
More News From Evolus, Inc.

Evolus to Report Fourth Quarter and Full-Year 2025 Financial Results on March 3, 2026

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it will report its fourth quarter and full-year 2025 financial results on Tuesday, March 3, 2026, after the U.S. financial markets close. Evolus management will host a conference call and live webcast to discuss these results at 4:30 p.m. ET that same day. A question-and-answer session will follow management’s...

Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a global performance beauty company with a focus on building an aesthetic portfolio, today reported the grant during December 2025, January 2026, and February 2026 of an aggregate of 153,218 restricted stock units (RSUs) and 34,952 stock options of the company’s common stock to 36 newly hired non-executive employees of the company. The awards were approved by the compensation committee of the company’s board of directors under...

Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2025 Net Revenue

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a global performance beauty company with a focus on building an aesthetic portfolio, today announced its preliminary, unaudited net revenue for the fourth quarter and full-year ended December 31, 2025. The preliminary unaudited results described in this press release are based on the most current information available to management and are subject to change until the audit of the company’s 2025 financial results is completed a...
Back to Newsroom